U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H25NO3.CH4O3S.3H2O
Molecular Weight 477.569
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAXOPRODIL MESYLATE

SMILES

O.O.O.CS(O)(=O)=O.C[C@@H]([C@@H](O)C1=CC=C(O)C=C1)N2CCC(O)(CC2)C3=CC=CC=C3

InChI

InChIKey=LUILKELNVBKKTG-ZOZJKLBQSA-N
InChI=1S/C20H25NO3.CH4O3S.3H2O/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17;1-5(2,3)4;;;/h2-10,15,19,22-24H,11-14H2,1H3;1H3,(H,2,3,4);3*1H2/t15-,19+;;;;/m0..../s1

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H25NO3
Molecular Weight 327.4174
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11249721

Traxoprodil (CP-101,606) is a potent, selective N-Methyl-D-aspartate (NMDA) receptor (NR2B subunit) antagonist under development by Pfizer for its potential as a neuroprotectant in head injury and neurodegenerative disease. It is in phase II trials in the US and in phase I in Japan for the potential treatment of head injury, such as, Depressive Disorder, Major and Parkinson's Disease. CP-101,606 does not protect against glutamate-induced neurotoxicity in cultured cerebellar neurons, up to a dose of 10 uM. These results are consistent with CP-101,606 being a potent NMDA antagonist, selective for the type of NMDA receptor associated with the hippocampus. Some further investigation revealed that CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
674 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
246 ng/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1370 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
856 ng × h/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.68 h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TRAXOPRODIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.995
healthy, ADULT
n = 11
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Population Size: 11
Sources: Page: p.995
0.75 mg/kg 1 times / hour multiple, intravenous
Highest studied dose
Dose: 0.75 mg/kg, 1 times / hour
Route: intravenous
Route: multiple
Dose: 0.75 mg/kg, 1 times / hour
Co-administed with::
levodopa(25mg, was administered orally)
Carbidopa
Sources: Page: p.5, 13
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 12
Sources: Page: p.5, 13
Other AEs: Abnormal thinking...
Other AEs:
Abnormal thinking (83.3%)
Sources: Page: p.5, 13
AEs

AEs

AESignificanceDosePopulation
Abnormal thinking 83.3%
0.75 mg/kg 1 times / hour multiple, intravenous
Highest studied dose
Dose: 0.75 mg/kg, 1 times / hour
Route: intravenous
Route: multiple
Dose: 0.75 mg/kg, 1 times / hour
Co-administed with::
levodopa(25mg, was administered orally)
Carbidopa
Sources: Page: p.5, 13
unhealthy, ADULT
n = 12
Health Status: unhealthy
Condition: Parkinson disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 12
Sources: Page: p.5, 13
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
2003 Jan
Gateways to clinical trials.
2004 Apr
Characterization of N-methyl-D-aspartate receptor subunits involved in acute ammonia toxicity.
2004 Jan
Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
2004 Jun 11
Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
2006
The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys.
2007 Dec
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
2008 Oct 15
Innovative approaches to treatment - refractory depression: The ketamine story.
2010 Apr
Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors.
2010 Aug
Patents

Patents

Sample Use Guides

CP 101,606 (TRAXOPRODIL) was administered at 0.25 mg/kg/hr for 2 hours followed by 0.12 mg/kg/hr for 2 hours, targeting a minimum plasma concentration of 60 ng/ml. “High dose” CP 101,606 was administered at 0.75 mg/kg/hr for 2 hours and then at 0.36 mg/kg/hr for 2 hours, targeting a minimum plasma concentration of 200 ng/ml. Matching placebo infusions were administered the control day. The study drug (CP-101,606 or placebo) were infused at a same infusion rates for each subject via a dedicated intravenous line.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:36:24 UTC 2023
Edited
by admin
on Fri Dec 15 15:36:24 UTC 2023
Record UNII
BD2A56I30W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAXOPRODIL MESYLATE
USAN  
USAN  
Official Name English
1-PIPERIDINEETHANOL, 4-HYDROXY-.ALPHA.-(4-HYDROXYPHENYL)-.BETA.-METHYL-4-PHENYL-, (.ALPHA.S,.BETA.S)-, METHANESULFONATE, HYDRATE (1:1:3)
Common Name English
CP-101606-27
Code English
TRAXOPRODIL MESILATE HYDRATE
WHO-DD  
Common Name English
TRAXOPRODIL MESILATE TRIHYDRATE
Common Name English
(αS,βS)-4-Hydroxy-α-(P-hydroxyphenyl)-β-methyl-4-phenyl-1-piperidineethanol methanesulfonate (salt), trihydrate
Common Name English
TRAXOPRODIL MESYLATE TRIHYDRATE
Common Name English
Traxoprodil mesilate hydrate [WHO-DD]
Common Name English
CP-101,606-27
Code English
TRAXOPRODIL MESYLATE [USAN]
Common Name English
1-PIPERIDINEETHANOL, 4-HYDROXY-.ALPHA.-(4-HYDROXYPHENYL)-.BETA.-METHYL-4-PHENYL-, (S-(R*,R*))-, METHANESULFONATE (SALT), TRIHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29707
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C61981
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
PUBCHEM
9826324
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
ChEMBL
CHEMBL17350
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
EPA CompTox
DTXSID60940514
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
MESH
C095106
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
CAS
189894-57-3
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
FDA UNII
BD2A56I30W
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
USAN
KK-59
Created by admin on Fri Dec 15 15:36:25 UTC 2023 , Edited by admin on Fri Dec 15 15:36:25 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY